Sign in / Join Now
ETFs & Funds
Don't know why FDA denied POSIDUR? It is almost exactly like Pacira's EXPAREL. Now strong buying opportunity!
FDA wants another clinical study to verify safety for labeled uses, this is not unusual for the FDA. Just delays approval
That's just great. Now I have to wait another two years until this takes off!
Add a reply...
Latest StockTalks »
people get DRRX breaking news and analysis by email alert.
Get email alerts on DRRX »
Get latest price
From other sites
Durect Stock Sees Short Interest Fall 19.6%
at TheStreet (Jan 12, 2017)
Short Interest In Durect Moves 21.5% Higher
at TheStreet (Nov 10, 2016)
DURECT Corporation Announces Update On DUR-928 Development Program
at TheStreet (Oct 31, 2016)
DURECT Corporation Invites You To Join Its Third Quarter 2016 Earnings Conference Call
at TheStreet (Oct 21, 2016)
Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection
at TheStreet (Sep 26, 2016)